Connect with us

Entrepreneur

‘There’s a lot of medical gaslighting’: the entrepreneur shaking up the fertility industry in South Asia

Published

on

Anna Haotanto, founder and CEO of Zora Health

Fertility treatments can be unnecessarily complicated and out of reach but they shouldn’t be, Anna Haotanto told herself when she stepped down from ABZD Capital – an investment and advisory firm she co-established – looking for a fresh start. 

Inspired by her own egg freezing experience and let down by the lack of innovation in reproductive care, she set up Zora Health, a Singapore-based digital platform that aims to simplify fertility care at no extra cost for the patients. Here, she tells us more.

Anna, tell us a bit about your background and what inspired you to create Zora Health.

My last role was the managing partner of ABZD Capital and I was on the board of directors for Gourmet Food Holdings after serving as the managing director and overseeing the company’s growth in technology, digital innovation, branding, marketing and human resources.

I also founded The New Savvy – Asia’s leading financial, investments and career platform for women. Before being a founder, I was in banking for 8 years in wealth management.

I’ve been working for 22 years, and I was ready for a break and a fresh start. I stepped down last year because we reached a big milestone and I was keen to explore more tech opportunities. In that period, I looked at a lot of ideas, but asked myself, “What problem do I feel passionate about? What is overlooked and underserved?”

It’s not about proving myself, but solving something I care deeply about. I’ve always been interested in healthcare. Throughout my journey, I’ve had a lot of health issues. Last year alone, I had five surgeries. I thought I was suffering from perimenopause and started learning more about the symptoms.

It was an interesting area that I didn’t know much about. I started deep diving, because if I have that problem, I might as well try to solve it or find somebody to help. I realised there were very few solutions here. However, I couldn’t find a single source of truth or a platform of trusted resources.

So, I went into fertility as egg freezing is a topic I’m familiar with as I’ve done it myself. It’s also a very overlooked US$54bn global market, and 44 per cent of treatments are in Asia.

Technology has changed a lot of the way we do things, the way we travel, the way we stay in hotels, and the way we commute. There are a lot of developments, but not in fertility care. In Southeast Asia, I believe, there are only three or four fertility tech companies, mostly hardware or e-commerce.

I thought it was a very interesting market: high quantum, underserved. But we don’t talk about it because there are barriers to entry, such as shame and guilt.

How would you describe Zora Health in a few words?

Zora Health is a one-stop reproductive health and family planning platform that integrates patients, corporate employers, and fertility care providers, simplifying the journey and enhancing accessibility for all parties.

Our comprehensive services include online and physical consultations with a global network of partner clinics, medical concierge services and expert support. We also provide corporate fertility education workshops to cultivate fertility-friendly work environments, which ultimately help companies attract and retain top talent.

What makes Zora Health different?

Our clients often encounter common barriers, such as lack of information, stigma surrounding fertility issues and concerns about the affordability of treatments. They are also unsure of their options, what the process is like and regulations in different countries. These barriers can significantly impact their family planning journey, leading to delays or hesitations in seeking care.

At Zora Health, we strive to address these challenges by providing personalised support, educational resources and partnerships with over 80 clinics across 16 countries to empower our clients to make informed decisions about their reproductive health.

We also provide corporate fertility education workshops to cultivate fertility-friendly work environments, which ultimately help companies attract and retain top talent.

Zora means light or dawn. To us, it signifies a new beginning, a new way of doing things. We are building solutions we wished existed.

Women’s health comes with a lot of stigma. How has this impacted you as a founder?

The more stigma and problems there are, the more opportunities we see for Zora Health. The more I speak to our patients and clients, the more I see how important the work is.

Over the past few months, I realised that fertility is a problem that people address when it’s a bit too late. A younger friend of mine was told that she could only retrieve one viable egg. She’s only 37, so I think it’s a real problem. It’s just a problem that has never been talked about.

How does it impact me? The work is very meaningful and honestly, I’m very surprised to have found something that I truly love and care deeply about. We have an opportunity to change lives and make an impact. Even when I pitch to investors, I tell them I’m not here for five years — I’m here for 10, 15 years. I hope this will be my last work because there’s nothing else I want in life.

What obstacles have you encountered on this journey?

I don’t like bringing up gender issues, but the problem exists. We know that two per cent of total funding goes to women. There are a lot of female analysts and associates, but they’re not the ones writing the cheques. When I fundraised, I experienced it myself.

One of the biggest challenges for femtech is that female healthcare is poorly understood. Most of the research money historically goes to male afflictions.

There’s also a lot of medical gaslighting. When my friends see doctors, they share their discomfort but are not understood. It’s not because doctors don’t want to solve the problem, but rather that they don’t understand it. There should be more research money spent on all this.

Two, if the people writing cheques are males, they may also need help understanding, not because they don’t want to, but because they are unaware. Many years ago, when speaking to a start-up founder in his office, I saw one of my friends who needed to pump breast milk.

She complained that she had to pump in the copier room. He was completely clueless when I asked the founder why he didn’t have a private room. He was only 33. It’s not necessarily a gender problem – at 33, I didn’t have kids and I didn’t know that you needed a room for privacy and pumping breast milk.

We’ve spoken to about 400 women now, and many women don’t know about the egg freezing process. I did it five years ago, and I still didn’t know the process until I wrote an article.

Where are you with Zora Health now?

We are serving our patients and have 80 clinic partners across 16 countries. In addition, we are currently focusing on working with corporations through corporate workshops and offering corporate benefits for reproductive health and family planning. This covers the whole spectrum of fertility, menopause, PCOS, endometriosis and more.

Where do you see the company in the future?

In the long term, our vision is to unlock possibilities for women’s healthcare in Asia. To provide women with choices so they can live their lives without limitations.

To do this, we need a few things. One: resources and knowledge. It’s about creating a knowledge platform for women. And then you need providers, and a large network of clinics. And last, which people don’t talk about, is financing.

When I was young, my mum had a few surgeries because of breast cancer. I was very scared because she was not eligible for insurance by the time I could buy her insurance.

Until today, I live with that fear. What happens if she has a life-threatening disease in the future? Can I afford it? Financing is very important, and that’s often something people miss.

Maybe one day I’ll have to use my service. I’m 40 this year. Struggling with PCOS for the past six years, it will be harder for me to get pregnant. If I ever want to have kids, I believe there is a high chance I need to have IVF and if I do, I will definitely be a Zora Health patient myself.

To receive the Femtech World newsletter, sign up here.

News

Sun Pharma to acquire Organon in US$11bn deal

Published

on

Indian pharmaceutical giant Sun Pharma has agreed to buy Organon for US$11.75bn in a deal aimed at expanding its women’s health and biosimilars business.

Organon, which was spun out of Merck in 2021, has built a portfolio of more than 70 women’s health and general medicines products, including biosimilars, sold in the US and about 140 other countries.

The acquisition would give Sun Pharma a broader presence in biosimilars, which are medicines designed to be highly similar to existing biological drugs, and strengthen its position in women’s health.

Dilip Shanghvi, executive chairman of Sun Pharma, said: “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”

The companies said the combined business would generate annual revenue of US$12.4bn, operate across 150 countries and rank among the top three companies globally in women’s health.

They also said it would become the seventh largest biosimilar player.

Sun Pharma said the deal would help grow its innovative medicines business and expand its biosimilars offering.

It added that the combined company would have 18 large markets each generating more than US$100m in revenue.

Organon’s largest markets include the US, Brazil, Canada, China and countries in the European Union. The company also has six manufacturing facilities across the EU and emerging markets.

The deal follows market speculation that began on 10 April, when Indian media reported that Sun Pharma had submitted an all-cash offer for Organon.

A later report said the offer had been revised to US$13bn. Sun Pharma shares rose about 7 per cent on India’s National Stock Exchange after the announcement.

Sun Pharma said it would acquire all of Organon’s issued and outstanding shares in cash, using a combination of available cash and committed bank financing. It also estimated synergies of about US$350m within two to four years of completion.

The company said the acquisition would strengthen its cash generation, with EBITDA and cash flow set to nearly double, supporting efforts to reduce the net debt to EBITDA ratio of 2.3 times resulting from the deal. EBITDA is a measure of operating performance before certain costs are deducted.

Organon reported revenue of US$6.2bn last year and adjusted EBITDA of US$1.9bn. It also reported debt of US$8.64bn, down from US$9.5bn when it separated from Merck, and a cash balance of US$574m.

In November, Organon announced plans to sell its JADA System, designed to control and treat abnormal postpartum uterine bleeding or haemorrhage, to Laborie Medical Technologies for up to US$465m. Net proceeds from the sale will contribute to Organon’s cash balance as of 31 March 2026.

Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The boards of both companies have approved the transaction.

Carrie Cox, executive chair of Organon, said: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”

The transaction is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.

Continue Reading

News

Women’s digital health market set to reach US$5.28 billion in 2026 – report

Published

on

The women’s digital health market is set to reach US$5.28bn in 2026, up from US$4.36bn in 2025, according to a new report.

That would represent annual growth of 20.9 per cent, driven by factors including greater smartphone use among women, wider uptake of telehealth and a stronger focus on preventive care.

The report said the market could reach US$11.47bn by 2030, with projected annual growth of 21.4 per cent over the forecast period.

It also pointed to rising awareness of gender-specific health needs, expansion among digital health start-ups, growing demand for personalised healthcare, investment in femtech innovation and the spread of AI-enabled diagnostics.

Wearables linked to health apps and wider use of remote monitoring tools are also expected to play a larger role, as companies focus on more preventive and joined-up care.

Smartphone use was highlighted as a major driver because mobile apps are increasingly being used for women’s health services, from menstrual cycle tracking to pregnancy support.

The report cited Eurostat data showing that in 2023, 89 per cent of EU residents aged 16 to 74 in urban areas accessed the internet via smartphones.

The report also said companies in the sector are developing new technology aimed at improving access to more personalised healthcare.

One example it gave was a 2024 collaboration between Algorand and the Self-Employed Women’s Association to launch a digital health passport for women in India’s informal economy using blockchain technology.

Recent mergers and acquisitions were also noted. In March 2023, Maven Clinic acquired Naytal to expand its services in the UK and Europe.

North America was identified as the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Companies named as key players included Flo Health Inc, Natural Cycles, Elvie, Bellabeat, Clue by Biowink, MobileODT Ltd., Glow, Veera Health, Biowink GmbH, Ava AG, Hims & Hers Health, Inc., The Women’s Wellness Centre, Elara Health, myGynaeDoc, Maven Clinic, Kindbody, Allara Health, Tia and Hera Med Ltd.

Continue Reading

Entrepreneur

Future Fertility raises Series A financing to scale AI tools redefining fertility care worldwide

Published

on

Future Fertility Inc. has announced the closing of a US$4.1 million Series A financing round.

The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany) and Whitecap Venture Partners, with participation from new investors Sandpiper Ventures, Gaingels, and Jolt VC.

The financing will accelerate Future Fertility’s commercial expansion into Asia-Pacific and support its entry into the United States, including planned FDA 510(k) clearance for additional products as part of a broader U.S. market entry strategy.

Proceeds will also advance the development of a broader AI platform, from egg assessment through to embryo transfer, designed to support clinicians, embryologists, and patients across the full IVF journey.

M Ventures and Whitecap have supported Future Fertility’s mission to translate AI innovation into meaningful clinical outcomes since the company’s earliest stages.

Oliver Hardick, investment director, M Ventures, said: “Future Fertility is addressing a critical unmet need in reproductive medicine with a differentiated AI platform grounded in clinical data and real-world workflow integration.

“We are excited to continue supporting the company and team because we believe its technology has the potential to improve decision-making for clinicians, bring greater clarity to patients, and help advance a more personalised standard of care in fertility treatment.”

Future Fertility’s AI platform addresses a long-standing gap in fertility care: historically, there has been no objective, clinically validated method for assessing egg quality (Gardner et al., 2025), despite it being one of the most important drivers of reproductive success.

The company’s suite of deep learning tools includes VIOLET™, MAGENTA™, and ROSE™, purpose-built for egg freezing, IVF, and egg donation respectively.

The tools are based on AI models trained and validated on more than 650,000 oocyte images and are deployed in over 300 clinics across 35 countries.

Rhiannon Davies, founding and managing partner, Sandpiper Ventures, said:  “The best outcomes in fertility care globally come from better data and smarter tools. Future Fertility understands that, and they’ve built a platform that delivers on it.

“Sandpiper is proud to back a team turning rigorous science into real results for patients and clinicians alike.”

Partnerships with the world’s leading fertility networks – including IVI RMA and Eugin Group across Latin America and Europe, FertGroup Medicina Reproductiva in Brazil, and most recently announced Kato Ladies Clinic in Japan –  reflect growing demand for objective, AI-powered oocyte assessment in fertility care. In the United States, ROSE™ is newly available under an FDA 513(g) determination.

Research shows that approximately 50 per cent of IVF patients do not understand their likelihood of success, and many discontinue treatment prematurely, even though cumulative success rates improve significantly with multiple cycles (McMahon et al., 2024).

By delivering earlier clarity on egg quality, Future Fertility’s tools support more informed conversations between clinicians and patients, helping set realistic expectations and guide decisions about next steps.

Future Fertility’s growing evidence base spans seven peer-reviewed publications in Human Reproduction, Reproductive BioMedicine Online, Fertility & Sterility, and Nature’s Scientific Reports, and more than 70 scientific abstracts accepted and presented with partner clinics at conferences worldwide.

Christine Prada, CEO, Future Fertility, said: “Fertility treatment is one of the most emotionally and physically demanding experiences a person can go through.

“Every patient deserves objective data, not just a best guess, to support better decisions at critical moments in their care.

“This funding means we can bring that clarity to more patients, in more countries, at a moment when it matters most.”

Find out more about Future Fertility at futurefertility.com

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.